EEF1A2 and breast cancer: Secondary issues were (1) the relationship between clinicopathological behavior and ALU and LINE-1 plasma biomarkers; and (2) quantification of the amount of cfDNA in early-stage BC patients compared with healthy controls with EEF1A2 gene copies, a target that we verified to have good accuracy for haploid genomes screened using ddPCR.